Clinical Trial

Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory Acute Myeloid Leukemia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-30.
Trial Details
NCT Number NCT06760260
Lead Sponsor Hrain Biotechnology Co., Ltd.
Collaborators: The First Affiliated Hospital of Soochow University
Conditions Acute Myeloid Leukemia (AML)
Enrollment 7 participants
Start Date 2022-01-26
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-07